All-trans-retinoic acid-induced myositis in a child with acute promyelocytic leukemia.
Anthracyclin-based regimens and all-transretinoic acid (ATRA, tretinoin) as differentiating agent are commonly utilized for the treatment of acute promylelocytic leukemia (APL). There are many adverse effects that may be seen during the use of ATRA in patients with APL. Of these, ATRA-induced myositis is rarely described in adults and rare in the children with APL. Herein, we report an 11-year-old girl with APL who developed ATRA-induced myositis during induction treatment.
Citak
Funda Erkasar
FE
Losev-Losante, Ankara Foundation of Children with Leukemia, Hospital For the Children with Leukemia, Ankara, Turkey.
Ezer
Ustun
U
Akkaya
Emel
E
Ozbulbul
Nilgun
N
Bahce
Muhterem
M
Kurekci
Ahmet Emin
AE
D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D002648:Child; D005260:Female; D006801:Humans; D015473:Leukemia, Promyelocytic, Acute / Q000150:complications* / Q000188:drug therapy; D009220:Myositis / Q000139:chemically induced*; D014212:Tretinoin / Q000009:adverse effects* / Q000627:therapeutic use
D000970:Antineoplastic Agents; D014212:Tretinoin